This edition of the Genetic Technology TOE depicts life sciences trends across synthetic biology and sequencing technology. Engineered chimeric molecules and promoters, nanobody platforms, next-generation RNA sequencing technologies coupled with machine learning systems, are some of the most relevant innovations profiled. Vector delivery platform technologies expected to undergo clinical studies in the coming quarter are also depicted.
The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Table of Contents
Recent Advances in Synthetic Biology and Sequencing Technology:
- Engineered Chimeric Molecule Targeting HER Genes
- Next-gen RNA Sequencing Coupled with Machine Learning
- Engineered Promoters May Hold Key to Controlling Gene Expression
- Nanobody Technology Facilitated Immunotherapy
Clinical Trial Analysis and Key Contacts:
- Clinical Trial Analysis of Vector-delivery Based Drugs
- Key Contacts
